1,160 results on '"Lebbe C"'
Search Results
2. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3. Oncodermatologie : bilan d’extension des tumeurs cutanées et sous-cutanées
4. Algorithmes de prise en charge thérapeutique du mélanome du stade I au stade IV. Recommandations de prise en charge du Groupe de cancérologie cutanée de la Société française de dermatologie
5. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
6. Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
7. Improved nationwide survival of sarcoma patients with a network of reference centers
8. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021
9. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years
10. Lymphedema and Kaposi sarcoma: A narrative review
11. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
12. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
13. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
14. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
15. Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?
16. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
17. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
18. Penoscrotal Paget's disease
19. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆
20. Rôle de la TEP FDG dans l’évaluation de l’extension locorégionale et à distance du mélanome
21. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
22. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
23. Mélanome au stade ganglionnaire : analyse du ganglion sentinelle, curage ganglionnaire, perspective des traitements adjuvants. Enquête nationale française sur les pratiques actuelles et envisagées
24. Développement, mise en œuvre et objectifs de CARADERM, réseau national cancers cutanés rares – partie carcinomes annexiels
25. Prise en charge des effets indésirables des immunothérapies en oncologie
26. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
27. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
28. Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016
29. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years
30. Quoi de neuf en oncodermatologie ?
31. Improved survival using specialized multidisciplinary board in sarcoma patients
32. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
33. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
34. Hypoxia inducible factor one alpha and human viral pathogens
35. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
36. A-367 - Whole transcriptome sequencing: Optimizing molecular classification and management of rare skin cancers
37. A-372 - Skin adnexal carcinomas DNA genomic profiling uncovers oncogenic pathways and potential therapeutic targets
38. A-179 - Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
39. A-283 - Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting
40. A-308 - A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
41. A-375 - Kindlin-3 inactivation mediates melanoma agressiveness through crosstalk with the collagen-activated tyrosine kinase receptor DDR1
42. A-387 - Discoidin domain receptor 1, a melanoma immunomodulator
43. Efficacy of neoadjuvant pembrolizumab in a primary cutaneous stage II non-operated melanoma
44. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
45. Traitement systémique des métastases cérébrales de mélanome
46. 60P MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
47. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
48. Recommandations de la SFORL pour la prise en charge des patients immunodéprimés atteints de tumeurs de la tête et du cou de point de départ cutané
49. French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin
50. 471 mTORC2: therapeutic target in resistant BRAF-mutated melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.